Clinical Trials Directory

Trials / Completed

CompletedNCT07200804

Relationship Between Serum Vitamin D and Atherosclerosis in Hemodialysis Patients

Exploring the Relationship Between Serum Vitamin D and Atherosclerosis in Hemodialysis Patients: A Cross-sectional Study

Status
Completed
Phase
Study type
Observational
Enrollment
90 (actual)
Sponsor
Ain Shams University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study aimed to check if there is a link between good vitamin D levels in the blood and subclinical atherosclerosis in people on hemodialysis.

Detailed description

Hemodialysis patients with End-Stage Renal Disease (ESRD) face a significantly elevated risk of cardiovascular disease (CVD) due to a complex interplay of factors. A 30-year-old HD patient faces a cardiovascular mortality risk equivalent to that of an 80-year-old in the general population, emphasizing the accelerated aging of the cardiovascular system in ESRD. Vitamin D may reduce inflammation and modulate immunity, lowering hypertension and dyslipidemia risks and possibly reversing vascular calcification. However, excessive supplementation can cause hypercalcemia.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTMeasurement of Serum Vitamin D LevelVitamin D is made of two types, named ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). Vitamin D2 is produced by converting ergosterol, a fungi and plants sterol, when it is exposed to light from the sun. Vitamin D3 is made differently, as it is formed in animal skin such as human skin with the help of 7-dehydrocholesterol when the skin is exposed to sunlight (UVB radiation).
OTHERMeasurement of Carotid Intima-Media ThicknessSamples were collected by measuring the carotid intima-media thickness (CIMT) with a Mind ray Real time ultrasound scanner DC-6 doppler machine that has a probe at a frequency of 7.5 MHz. The measurement was done from three different sites each 1 cm proximal to the carotid bulb. The average of three values was taken to determine the final value. If CIMT \> 0.8 mm, it was defined as thickened. The measurements adhered to the Mannheim CIMT Consensus (2004-2006)

Timeline

Start date
2021-06-01
Primary completion
2021-12-01
Completion
2021-12-01
First posted
2025-10-01
Last updated
2025-10-01

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07200804. Inclusion in this directory is not an endorsement.